It's time to buy these 2 fallen ASX shares again: expert

One professional has named a pair of beaten-down stocks he that thinks is ready for a massive rebound.

If you think back to 2019, life was much simpler.

It was only three years ago, but no one outside of the medical profession had heard of the abbreviation COVID and inflation was non-existent. 

And if you look over investment articles such as this published back in 2019, there are some names often repeated.

But many of those former darlings have since endured a brutal period after the pandemic arrived, and have not really recovered since.

One expert, though, reckons it's time to revisit two of those fallen stars:

two smiling people, a man and a woman, raise a hand in a wave as they are tethered to each other while they skydive against a clear sky with a covering of clouds below before their parachute opens.

Image source: Getty Images

Forget China, there is growth elsewhere

Investors in Kiwi company A2 Milk Company Ltd (ASX: A2M) have long been waiting for a turnaround.

After gaining a stunning 3,400% in the first five years after its 2015 listing, the shares have lost a sorry 77% since July 2020.

"This infant formula company has been facing supply chain issues and margin pressure from increasing competition, resulting in a major valuation decline in recent years," Catapult Wealth financial adviser Tim Haselum told The Bull.

But he reckons it's now time to buy the dairy producer.

"Even without strong growth in China, A2 Milk is expanding in New Zealand and the US," said Haselum.

"Also, new markets in Malaysia, Singapore and Vietnam could lead to a recovery in 2023 and beyond."

It could also have some unexpected tricks up its sleeve.

"With a strong net cash position, A2 Milk has plenty of firepower for mergers and acquisitions."

The wider finance community is torn on the stock. According to CMC Markets, four of 15 analysts rate it as a buy while three are advising clients to sell, with the rest neutral.

50% profit growth? Yes, please

Technology shares have suffered both in Australia and the US, and Pro Medicus Limited (ASX: PME) is no exception.

The share price for the medical software maker has dipped more than 23% for the year so far.

Despite this, the price-to-earnings (P/E) ratio remains at an astronomical 133, according to Google Finance.

This would not stop Haselum from buying it right now.

"This medical imaging software provider is aggressively expanding overseas, particularly in the US, which accounts for about 70% of revenue."

He especially loved the latest results, which were up significantly from the previous year.

"The company announced a first-half 2022 net profit of $20.68 million, up 52.7% on the prior corresponding period," said Haselum.

"Given new contract wins and renewals, we believe Pro Medicus can justify its relatively high price/earnings ratio."

The analyst community has more conviction on Pro Medicus compared to A2 Milk. Six out of eight analysts surveyed by CMC Markets currently rate the tech company as a "strong buy".

Motley Fool contributor Tony Yoo owns A2 Milk. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Pro Medicus Ltd. The Motley Fool Australia owns and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

Woman with her fingers crossed and eyes shut.
Broker Notes

7 ASX 200 shares in the buy zone as optimism returns to the market: experts

Brokers reaffirmed their buy calls on Liontown, Rio Tinto, Xero, and others this week.

Read more »

ASX shares broker ratings represented by three different coloured buttons.
Broker Notes

6 ASX shares upgraded and downgraded by the experts this week

Brokers have changed their ratings and 12-month price targets on Qantas, Codan, and others. 

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Broker Notes

Buy, hold, sell: CSL, NextDC, PLS shares

Mark Elzayed from Vestra Capital explains his ratings on three ASX 200 shares.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Eagers Automotive, REA Group, National Australia Bank: Buy, sell, or hold?

The leader of this pack might surprise.

Read more »